Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about INBX, unsubscribe in one click. Privacy
| PDUFA Date | Drug | Indication | Type | PoA | Options-implied move |
|---|---|---|---|---|---|
| 2027-04-14 | ozekibart | unresectable or metastatic conventional chondrosarcoma | BLA | 61% | ±51% by May 21 |
Options-implied move = price of the at-the-money straddle for the first option expiry after the PDUFA date, as a share of the stock price (Yahoo Finance quotes, Nov 17). It prices every move until that expiry, not only the FDA decision.
PoA = estimated probability of approval: base rates calibrated against BioRadar's verified FDA outcomes, adjusted for application type, modality, therapy area, cash runway and problems the FDA has raised with the application, as the company has disclosed them. Not investment advice. See the full PDUFA calendar →
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Ordastobart (INBRX-106) | Head and Neck Squamous Cell Carcinoma (HNSCC) | Phase 2/3 · NCT06295731 | Recruiting |
| Carboplatin AUC-5 | Solid Tumor | Phase 1/2 · NCT04198766 | Recruiting |
| Carboplatin AUC-6 | Solid Tumor | Phase 1/2 · NCT04198766 | Recruiting |
| Nab-paclitaxel | Solid Tumor | Phase 1/2 · NCT04198766 | Recruiting |
| Ozekibart (INBRX-109) | Conventional Chondrosarcoma | Phase 2 · NCT04950075 | Active not recruiting |
| Trifluridine and Tipiracil Hydrochloride | Ewing Sarcoma | Phase 1 · NCT03715933 | Recruiting |
| Irinotecan | Ewing Sarcoma | Phase 1 · NCT03715933 | Recruiting |
| Enristomig (INBRX-105) | Metastatic Solid Tumors | Phase 1 · NCT03809624 | Terminated |
| INBRX-101/rhAAT-Fc | Alpha-1 Antitrypsin Deficiency | Phase 1 · NCT03815396 | Completed |
Also used in these trials (approved or third-party drugs, not INBX's own candidates): Pembrolizumab, Cisplatin, Paclitaxel, Gemcitabine Hydrochloride, Pemetrexed Disodium, Temozolomide, Bevacizumab, Leucovorin, Fluorouracil, Carboplatin.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
INBX holds $199.5M in cash and short-term investments (as of Sep 30, 2026) and burns about $32.3M/quarter from operations, an estimated runway of 18.5 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 31 · Moderate
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when INBX files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Perceptive Advisors LLC | Institution (13G, 5%+) | 1,489,443 | 10.12% | 2026-06-30 |
| VIKING GLOBAL INVESTORS LP 10% owner |
Insider | 1,383,621 | 9.40% | 2026-06-30 |
| Inhibrx, Inc. 10% owner |
Insider | 1,157,926 | 7.87% | 2024-05-29 |
| Sanofi | Institution (13F) | 1,157,926 | 7.87% | 2026-09-30 |
| Morgan Stanley | Institution (13G, 5%+) | 1,155,416 | 7.85% | 2025-12-31 |
| Jon Faiz Kayyem Director · +55,000 options |
Insider | 1,074,046 | 7.30% | 2026-09-23 |
| Mark Lappe Chief Executive Officer, Director · +300,000 options |
Insider | 970,453 | 6.59% | 2026-10-14 |
| Schonfeld Strategic Advisors LLC | Institution (13G, 5%+) | 952,959 | 6.47% | 2026-09-30 |
| HighTower Advisors, LLC | Institution (13F) | 884,441 | 6.01% | 2026-09-30 |
| BlackRock, Inc. | Institution (13G, 5%+) | 768,130 | 5.22% | 2025-12-31 |
| TIG Advisors, LLC | Institution (13F) | 677,789 | 4.61% | 2026-09-30 |
| State Street Corporation | Institution (13F) | 565,749 | 3.84% | 2026-09-30 |
Share count 14,717,660 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-10-14 filed 2026-10-14 |
Lappe Mark |
Purchase (P) | 2,470 | $84.07 | 743,018 |
| 2026-10-14 filed 2026-10-14 |
Lappe Mark |
Purchase (P) | 2,470 | $85.00 | 745,488 |
| 2026-10-14 filed 2026-10-14 |
Lappe Mark |
Purchase (P) | 100 | $85.76 | 745,588 |
| 2026-10-14 filed 2026-10-14 |
Lappe Mark |
Purchase (P) | 2,449 | $84.07 | 167,449 |
| 2026-10-14 filed 2026-10-14 |
Lappe Mark |
Purchase (P) | 2,451 | $85.00 | 169,900 |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for INBX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →